- Home
- HQL vs CKPT Comparison
HQL vs CKPT Comparison
Compare HQL & CKPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQL
- CKPT
- Stock Information
- Founded
- HQL 1992
- CKPT 2014
- Country
- HQL United States
- CKPT United States
- Employees
- HQL N/A
- CKPT N/A
- Industry
- HQL Investment Managers
- CKPT Biotechnology: Pharmaceutical Preparations
- Sector
- HQL Finance
- CKPT Health Care
- Exchange
- HQL Nasdaq
- CKPT Nasdaq
- Market Cap
- HQL 368.7M
- CKPT 335.9M
- IPO Year
- HQL N/A
- CKPT 2017
- Fundamental
- Price
- HQL $11.82
- CKPT $4.04
- Analyst Decision
- HQL
- CKPT Buy
- Analyst Count
- HQL 0
- CKPT 3
- Target Price
- HQL N/A
- CKPT $4.33
- AVG Volume (30 Days)
- HQL 120.9K
- CKPT 1.7M
- Earning Date
- HQL 01-01-0001
- CKPT 05-09-2025
- Dividend Yield
- HQL 11.56%
- CKPT N/A
- EPS Growth
- HQL N/A
- CKPT N/A
- EPS
- HQL 0.79
- CKPT N/A
- Revenue
- HQL N/A
- CKPT $41,000.00
- Revenue This Year
- HQL N/A
- CKPT $102,182.93
- Revenue Next Year
- HQL N/A
- CKPT $351.71
- P/E Ratio
- HQL $17.08
- CKPT N/A
- Revenue Growth
- HQL N/A
- CKPT N/A
- 52 Week Low
- HQL $11.34
- CKPT $1.38
- 52 Week High
- HQL $14.37
- CKPT $4.50
- Technical
- Relative Strength Index (RSI)
- HQL 42.79
- CKPT 63.60
- Support Level
- HQL $11.59
- CKPT $3.94
- Resistance Level
- HQL $11.93
- CKPT $4.06
- Average True Range (ATR)
- HQL 0.42
- CKPT 0.05
- MACD
- HQL 0.03
- CKPT -0.03
- Stochastic Oscillator
- HQL 56.95
- CKPT 83.33
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.